BioCentury | Oct 28, 2020
Distillery Therapeutics

Small molecule ERG, FLI1 inhibitor identified for retinopathy of prematurity

...Retinopathy of prematurityA tool compound that inhibits multiple E26 transformation-specific transcription factors, including ERG and FLI1...
...the ERG and FLI1 inhibitor in mouse models.TARGET/MARKER/PATHWAY: v-ets erythroblastosis virus E26 oncogene homolog (ERG); Friend leukemia virus integration 1 (FLI1)EXPERIMENTAL...
...Medical Research Foundation, Oklahoma City, Okla.email: courtney-griffin@omrf.org Claire Quang Oklahoma Medical Research Foundation v-ets erythroblastosis virus E26 oncogene homolog (ERG) Friend leukemia virus integration 1 (FLI1) Ophthalmic Retinopathy...
BioCentury | Sep 11, 2020
Product Development

COVID-19 should spur massive investment in science and technology, Regeneron’s Yancopoulos says: a BioCentury audio interview

In addition to preparing for future pandemics, the U.S. should increase its investments in science and technology by orders of magnitude to head off crippling onslaughts of disease, Regeneron’s George Yancopoulos told BioCentury. In a...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

Modalis paved its way to a public listing on the Tokyo Stock Exchange’s Mothers through a series of early pharma partnerships leveraging its CRISPR-based gene modulation platform. Shares of Modalis Therapeutics...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

Nura Bio emerged from stealth last week with a $73 million series A and strategy to tackle neurological disorders based on two prevailing theories -- increasing neuroprotection and reducing neuroinflammation. Led by Vir and Biogen...
BioCentury | Jun 23, 2020
Distillery Therapeutics

Repurposing antimalarial drug lumefantrine for glioblastoma

...DISEASE CATEGORY: Cancer INDICATION: Brain cancer The antimalarial drug lumefantrine, an FLI1 inhibitor, could treat glioblastoma...
...and unapproved treatments for Ewing sarcoma, which is linked to the EWSR1-FLI1 fusion protein, for FLI1...
...AG (NYSE:NVS; SIX:NOVN) markets lumefantrine in combination with artemether as Coartem to treat malaria. TARGET/MARKER/PATHWAY: Friend leukemia virus integration 1 (FLI1)...
BioCentury | May 9, 2020
Deals

The Roche-Arrakis deal in their own words

The April deal between Arrakis and Roche started with dinner in Basel and closed over Zoom. In a podcast conversation with BioCentury, the architects of the deal, James Sabry and Michael Gilman, describe how the...
BioCentury | Apr 1, 2020
Product Development

A primer on the new coronavirus and COVID-19: BioCentury editors in conversation

The rapid pace at which COVID-19 has transformed society has rippled through the biopharma industry, affecting not only companies’ business strategies, but their product pipelines and priorities as many of them adapt on the fly...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis. The setbacks came as...
BioCentury | Mar 26, 2020
Product Development

Survey says: Companies seek regulatory flexibility as COVID-19 makes clinical disruptions the new norm

COVID-19 is no longer an approaching threat to clinical trials; now the concern for biotechs is how to manage their trials through the crisis. A joint survey from BioCentury and BIO finds on-the-fly protocol amendments...
BioCentury | Mar 26, 2020
Deals

Pharmas on one page with action plan to solve COVID-19 together

A grand-scale behind-the-scenes effort by the pharmaceutical companies is under way to expedite the creation of therapies and vaccines to treat COVID-19. According to the participants who spoke with BioCentury under conditions of anonymity, R&D...
Items per page:
1 - 10 of 391